Qualitas Funds' News

Return to Qualitas Funds news
  • Portfolio transactions

Qualitas Funds IV – Univo IRB

We are pleased to announce Univo IRB has been added to the Qualitas Funds IV portfolio through the acquisition by one of our GPs in the United States.

Established in 2016, Univo IRB is an Independent Review Board (IRB) focused on serving biotech and small pharma sectors. The company specializes in the ethical review of Phase I-IV pharmaceutical, device, biologic, behavioral, and psycho-social research. It prioritizes efficiency and promptness in its operations while maintaining a strong focus on advocating for patient rights throughout its processes.